CONMED Corp. 10-Q Summary: Quarter Ended March 31, 1995
Business Context and Reporting Period
CONMED Corporation, a developer and manufacturer of disposable medical products and devices, filed its Form 10-Q for the quarter ended March 31, 1995. The reporting period reflects the impact of the acquisition of Birtcher Medical Systems on March 14, 1995, which was accounted for using the purchase method. The financial statements are unaudited.
Key Financial Metrics
| Metric | Q1 1995 | Q1 1994 |
|---|---|---|
| Net Sales | $19,753,000 | $17,838,000 |
| Net Income | $1,840,000 | $1,147,000 |
| Earnings Per Share | $0.27 | $0.18 |
| Gross Margin | 45.7% | 43.9% |
| Operating Cash Flow | $2,527,000 | $2,966,000 |
| Total Debt (Current + Long-term) | $20,000,000 | $9,375,000 |
| Cash and Equivalents | $955,000 | $3,615,000 |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 10.7% to $19.75 million, driven significantly by the inclusion of Birtcher Medical Systems for approximately two weeks of the quarter.
- Profitability: Net income rose 60.4% to $1.84 million. Gross margin improved to 45.7% due to economies of scale and manufacturing efficiencies, despite higher R&D spending ($664k vs $525k).
- Balance Sheet Expansion: Total assets increased from $62.1 million to $102.4 million, primarily due to $40.1 million in goodwill and $5.8 million in intangible assets recorded from the Birtcher acquisition.
- Debt Levels: Total debt obligations increased substantially to $20 million ($3 million current, $17 million long-term) following the refinancing of existing bank debt and assumption of acquisition liabilities.
- Liquidity: Cash and cash equivalents declined to $955,000 from $3.615 million, largely due to $8.28 million used to liquidate liabilities associated with the Birtcher acquisition.
Outlook, Risks, and Management Commentary
- Acquisition Impact: Management anticipates selling and administrative costs will increase in future quarters as the Birtcher acquisition is fully integrated, though expense as a percentage of sales is expected to decline due to productivity gains.
- Capital Expenditures: The company purchased land and a building in Rome, New York for $1.2 million to support manufacturing expansion.
- Legal Contingency: An appellate court affirmed a $2.1 million patent infringement damage award against a competitor. The company states adequate reserves were made in 1993 and no additional charge is required, though cash is available to cover the award if necessary.
- Liquidity Position: Management believes cash from operations and a $30 million secured term loan (with $20 million outstanding) plus a $10 million revolving credit facility (unused) provide sufficient liquidity for operations and capital expenditures.
Investor Verification Checklist
- Verify the final allocation of the $17.75 million purchase price for the Birtcher acquisition, as management noted preliminary estimates may be re-allocated within 12 months.
- Monitor the integration of Birtcher Medical Systems to confirm projected sales productivity and the anticipated decline in selling/administrative expense ratios.
- Review the status of the $2.1 million patent litigation reserve to ensure no unexpected additional charges are required.
- Assess the impact of increased interest rates and higher debt levels on future interest expense and net income.
- Confirm the utilization of the $10 million revolving credit facility if working capital needs exceed current cash reserves.